Natural Product (NP) Details
General Information of the NP (ID: NP8133) | |||||
---|---|---|---|---|---|
Name |
Cucurbitacin I
|
||||
Synonyms |
Cucurbitacin I; 2222-07-3; Elatericin B; Cucurbitacine (I); 1,2-Dehydroelatericin A; UNII-SHQ47990PH; CHEBI:3947; SHQ47990PH; (8S,9R,10R,13R,14S,16R,17R)-17-[(E,2R)-2,6-dihydroxy-6-methyl-3-oxohept-4-en-2-yl]-2,16-dihydroxy-4,4,9,13,14-pentamethyl-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthrene-3,11-dione; JSI-124; NSC521777; NSC 521777; NSC-521777; MLS002702902; 19-nor-9.beta.,5,23-triene-3,11,22-trione, 9-methyl-2,16,20,25-tetrahydroxy-; JSI 124; 19-Norlanosta-1,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.)- (VA; EINECS 218-736-8; NSC 112167; CUCURBITACCINE (I); CHEMBL387737; SCHEMBL2523066; SCHEMBL15914446; DTXSID501015546; HY-N1405; ZINC4097803; LMST01010110; NSC112167; AKOS024456675; CS-5431; NCGC00388208-02; 19-Nor-9-beta,10-alpha-lanosta-1,5,23-triene-3,11,22-trione, 9-methyl-2,16,20,25-tetrahydroxy-; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9beta,10alpha,16alpha)-; 2,16alpha,20,25-Tetrahydroxy-9beta-methyl-10alpha-19-norlanosta-1,5,23(E)-triene-3,11,22-trione; A4512; C08800; 222C073; Q27106265; (4R,9beta,16alpha,23E)-2,16,20,25-tetrahydroxy-9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene-1,11,22-trione; (8S,9R,10R,13R,14S,16R,17R)-17-[(E,1R)-1,5-dihydroxy-1,5-dimethyl-2-oxo-hex-3-enyl]-2,16-dihydroxy-4,4,9,13,14-pentamethyl-8,10,12,15,16,17-hexahydro-7H-cyclopenta[a]phenanthrene-3,11-dione; (9?,10?,16?,23E)-2,16,20,25-Tetrahydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.,23E)-; 19-Norlanosta-1,5,23-triene-3,11,22-trione, 2,16,20,25-tetrahydroxy-9-methyl-, (9beta,10alpha,16alpha)- (VAN) (9CI)
Click to Show/Hide
|
||||
Species Origin | Citrullus lanatus ... | Click to Show/Hide | |||
Citrullus lanatus | |||||
Disease | Ovarian cancer [ICD-11: 2C73] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C30H42O7
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1(C2=CCC3C4(CC(C(C4(CC(=O)C3(C2C=C(C1=O)O)C)C)C(C)(C(=O)C=CC(C)(C)O)O)O)C)C
|
||||
InChI |
1S/C30H42O7/c1-25(2,36)12-11-21(33)30(8,37)23-19(32)14-27(5)20-10-9-16-17(13-18(31)24(35)26(16,3)4)29(20,7)22(34)15-28(23,27)6/h9,11-13,17,19-20,23,31-32,36-37H,10,14-15H2,1-8H3/b12-11+/t17-,19-,20+,23+,27+,28-,29+,30+/m1/s1
|
||||
InChIKey |
NISPVUDLMHQFRQ-MKIKIEMVSA-N
|
||||
CAS Number |
CAS 2222-07-3
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Ionizing radiation | Renal Insufficiency | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Cells derived from NSCLC patients | Non-small cell lung cancer | Homo sapiens | |||
Experimental
Result(s) |
Targeting STAT3 signaling in CD133-positive NSCLC cells with cucurbitacin I suppressed CSC-like properties and enhanced chemoradiotherapy response. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | COLO 205 | CVCL_0218 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Cucurbitacin I inhibits cell migration and invasion and enhances chemosensitivity in colon cancer. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Apoptosis regulator Bcl-xL (BCL-xL) | Molecule Info | [2] | |
Bcl2 antagonist of cell death (BAD) | Molecule Info | [2] | ||
Inositol-3-phosphate synthase 1 (SPAG9) | Molecule Info | [4] | ||
Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [4] | ||
STAT factor 3 (STAT3) | Molecule Info | [2] | ||
Stress-activated protein kinase 2a (SAPK2A) | Molecule Info | [4] | ||
KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
2 | NF-kappa B signaling pathway | |||
3 | PI3K-Akt signaling pathway | |||
4 | Apoptosis | |||
5 | Jak-STAT signaling pathway | |||
6 | Amyotrophic lateral sclerosis (ALS) | |||
7 | Toxoplasmosis | |||
8 | HTLV-I infection | |||
9 | Pathways in cancer | |||
10 | Transcriptional misregulation in cancer | |||
11 | Pancreatic cancer | |||
12 | Chronic myeloid leukemia | |||
13 | Small cell lung cancer | |||
14 | Chemokine signaling pathway | |||
15 | HIF-1 signaling pathway | |||
16 | FoxO signaling pathway | |||
17 | Signaling pathways regulating pluripotency of stem cells | |||
18 | Prolactin signaling pathway | |||
19 | Adipocytokine signaling pathway | |||
20 | Hepatitis C | |||
21 | Hepatitis B | |||
22 | Measles | |||
23 | Epstein-Barr virus infection | |||
24 | Viral carcinogenesis | |||
25 | Proteoglycans in cancer | |||
26 | MicroRNAs in cancer | |||
27 | Acute myeloid leukemia | |||
28 | Inflammatory bowel disease (IBD) | |||
29 | Protein processing in endoplasmic reticulum | |||
30 | MAPK signaling pathway | |||
31 | Rap1 signaling pathway | |||
32 | Sphingolipid signaling pathway | |||
33 | Adrenergic signaling in cardiomyocytes | |||
34 | VEGF signaling pathway | |||
35 | Osteoclast differentiation | |||
36 | Platelet activation | |||
37 | Toll-like receptor signaling pathway | |||
38 | NOD-like receptor signaling pathway | |||
39 | RIG-I-like receptor signaling pathway | |||
40 | T cell receptor signaling pathway | |||
41 | Fc epsilon RI signaling pathway | |||
42 | TNF signaling pathway | |||
43 | Leukocyte transendothelial migration | |||
44 | Neurotrophin signaling pathway | |||
45 | Retrograde endocannabinoid signaling | |||
46 | Dopaminergic synapse | |||
47 | Inflammatory mediator regulation of TRP channels | |||
48 | GnRH signaling pathway | |||
49 | Progesterone-mediated oocyte maturation | |||
50 | Epithelial cell signaling in Helicobacter pylori infection | |||
51 | Shigellosis | |||
52 | Salmonella infection | |||
53 | Pertussis | |||
54 | Leishmaniasis | |||
55 | Chagas disease (American trypanosomiasis) | |||
56 | Tuberculosis | |||
57 | Influenza A | |||
NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
2 | TGF_beta_Receptor Signaling Pathway | |||
3 | Notch Signaling Pathway | |||
4 | IL5 Signaling Pathway | |||
5 | FSH Signaling Pathway | |||
6 | TCR Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | CCKR signaling map ST | |||
3 | Angiogenesis | |||
4 | EGF receptor signaling pathway | |||
5 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
6 | Interleukin signaling pathway | |||
7 | JAK/STAT signaling pathway | |||
8 | PDGF signaling pathway | |||
9 | Ras Pathway | |||
10 | Alzheimer disease-amyloid secretase pathway | |||
11 | B cell activation | |||
12 | FGF signaling pathway | |||
13 | Interferon-gamma signaling pathway | |||
14 | Oxidative stress response | |||
15 | Parkinson disease | |||
16 | TGF-beta signaling pathway | |||
17 | Toll receptor signaling pathway | |||
18 | VEGF signaling pathway | |||
19 | p53 pathway feedback loops 2 | |||
20 | p38 MAPK pathway | |||
Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
Pathway Interaction Database | IL2 signaling events mediated by PI3K | Click to Show/Hide | ||
2 | IL3-mediated signaling events | |||
3 | Caspase Cascade in Apoptosis | |||
4 | EPO signaling pathway | |||
5 | IL2 signaling events mediated by STAT5 | |||
6 | GMCSF-mediated signaling events | |||
7 | IL27-mediated signaling events | |||
8 | Signaling events mediated by PTP1B | |||
9 | IL12-mediated signaling events | |||
10 | Signaling events mediated by TCPTP | |||
11 | Signaling events mediated by HDAC Class I | |||
12 | IL2-mediated signaling events | |||
13 | CXCR4-mediated signaling events | |||
14 | EGF receptor (ErbB1) signaling pathway | |||
15 | IFN-gamma pathway | |||
16 | ErbB1 downstream signaling | |||
17 | ErbB2/ErbB3 signaling events | |||
18 | IL6-mediated signaling events | |||
19 | PDGFR-beta signaling pathway | |||
20 | Neurotrophic factor-mediated Trk receptor signaling | |||
21 | IL23-mediated signaling events | |||
22 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
23 | FGF signaling pathway | |||
24 | RAC1 signaling pathway | |||
25 | Notch-mediated HES/HEY network | |||
26 | IL12 signaling mediated by STAT4 | |||
27 | Endothelins | |||
28 | BCR signaling pathway | |||
29 | p73 transcription factor network | |||
30 | p38 MAPK signaling pathway | |||
31 | Atypical NF-kappaB pathway | |||
32 | IL4-mediated signaling events | |||
33 | CD40/CD40L signaling | |||
34 | Regulation of p38-alpha and p38-beta | |||
35 | CDC42 signaling events | |||
36 | Angiopoietin receptor Tie2-mediated signaling | |||
37 | FAS (CD95) signaling pathway | |||
38 | Thromboxane A2 receptor signaling | |||
39 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
40 | Glucocorticoid receptor regulatory network | |||
41 | Rapid glucocorticoid signaling | |||
42 | Regulation of Androgen receptor activity | |||
43 | ATF-2 transcription factor network | |||
44 | p38 signaling mediated by MAPKAP kinases | |||
45 | Retinoic acid receptors-mediated signaling | |||
46 | CXCR3-mediated signaling events | |||
47 | Signaling mediated by p38-alpha and p38-beta | |||
48 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
49 | p53 pathway | |||
50 | S1P2 pathway | |||
51 | Trk receptor signaling mediated by the MAPK pathway | |||
52 | VEGFR3 signaling in lymphatic endothelium | |||
53 | Regulation of retinoblastoma protein | |||
Reactome | BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | Click to Show/Hide | ||
2 | The NLRP1 inflammasome | |||
3 | Interleukin-6 signaling | |||
4 | Senescence-Associated Secretory Phenotype (SASP) | |||
5 | POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | |||
6 | Transcriptional regulation of pluripotent stem cells | |||
7 | Growth hormone receptor signaling | |||
8 | NOD1/2 Signaling Pathway | |||
9 | p38MAPK events | |||
10 | ERK/MAPK targets | |||
11 | Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |||
12 | Oxidative Stress Induced Senescence | |||
13 | CDO in myogenesis | |||
14 | DSCAM interactions | |||
15 | ADP signalling through P2Y purinoceptor 1 | |||
16 | Platelet sensitization by LDL | |||
17 | VEGFA-VEGFR2 Pathway | |||
18 | activated TAK1 mediates p38 MAPK activation | |||
19 | Activation of the AP-1 family of transcription factors | |||
20 | KSRP (KHSRP) binds and destabilizes mRNA | |||
WikiPathways | IL-6 signaling pathway | Click to Show/Hide | ||
2 | IL-3 Signaling Pathway | |||
3 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
4 | Apoptosis | |||
5 | Amyotrophic lateral sclerosis (ALS) | |||
6 | TNF alpha Signaling Pathway | |||
7 | IL-7 Signaling Pathway | |||
8 | Leptin signaling pathway | |||
9 | Intrinsic Pathway for Apoptosis | |||
10 | Apoptosis Modulation and Signaling | |||
11 | Serotonin Receptor 2 and STAT3 Signaling | |||
12 | Notch Signaling Pathway | |||
13 | Interferon type I signaling pathways | |||
14 | EPO Receptor Signaling | |||
15 | TGF Beta Signaling Pathway | |||
16 | IL-2 Signaling Pathway | |||
17 | EGF/EGFR Signaling Pathway | |||
18 | IL-4 Signaling Pathway | |||
19 | Signaling of Hepatocyte Growth Factor Receptor | |||
20 | Kit receptor signaling pathway | |||
21 | Nuclear Receptors Meta-Pathway | |||
22 | Estrogen Receptor Pathway | |||
23 | TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||
24 | Dopaminergic Neurogenesis | |||
25 | Transcriptional regulation of pluripotent stem cells | |||
26 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
27 | Signaling by SCF-KIT | |||
28 | Interleukin-6 signaling | |||
29 | Growth hormone receptor signaling | |||
30 | JAK/STAT | |||
31 | PDGF Pathway | |||
32 | BDNF signaling pathway | |||
33 | Oncostatin M Signaling Pathway | |||
34 | Adipogenesis | |||
35 | Interleukin-11 Signaling Pathway | |||
36 | AGE/RAGE pathway | |||
37 | Prostate Cancer | |||
38 | TSLP Signaling Pathway | |||
39 | IL-9 Signaling Pathway | |||
40 | IL17 signaling pathway | |||
41 | Regulation of Microtubule Cytoskeleton | |||
42 | TSH signaling pathway | |||
43 | Cell Differentiation - Index | |||
44 | Cell Differentiation - meta | |||
45 | Signaling by PDGF | |||
46 | NGF signalling via TRKA from the plasma membrane | |||
47 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
48 | MicroRNAs in cardiomyocyte hypertrophy | |||
49 | Physiological and Pathological Hypertrophy of the Heart | |||
50 | Androgen receptor signaling pathway | |||
51 | IL-5 Signaling Pathway | |||
52 | Oxidative Stress | |||
53 | Transcriptional activation by NRF2 | |||
54 | NRF2 pathway | |||
55 | Aryl Hydrocarbon Receptor Pathway | |||
56 | Mesodermal Commitment Pathway | |||
57 | Aryl Hydrocarbon Receptor | |||
58 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
59 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
60 | Toll-like receptor signaling pathway | |||
61 | Monoamine Transport | |||
62 | Serotonin HTR1 Group and FOS Pathway | |||
63 | TCR Signaling Pathway | |||
64 | Senescence and Autophagy in Cancer | |||
65 | Insulin Signaling | |||
66 | MAPK Cascade | |||
67 | p38 MAPK Signaling Pathway | |||
68 | MAPK Signaling Pathway | |||
69 | TGF beta Signaling Pathway | |||
70 | Cardiac Hypertrophic Response | |||
71 | MAP kinase activation in TLR cascade | |||
72 | Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||
73 | Nanoparticle-mediated activation of receptor signaling | |||
74 | Structural Pathway of Interleukin 1 (IL-1) | |||
75 | Alpha 6 Beta 4 signaling pathway | |||
76 | Cardiac Progenitor Differentiation | |||
77 | Integrated Pancreatic Cancer Pathway | |||
78 | Parkinsons Disease Pathway | |||
79 | Corticotropin-releasing hormone | |||
80 | B Cell Receptor Signaling Pathway | |||
81 | TWEAK Signaling Pathway | |||
82 | FSH signaling pathway | |||
83 | RANKL/RANK Signaling Pathway | |||
84 | miR-targeted genes in muscle cell - TarBase | |||
85 | miR-targeted genes in lymphocytes - TarBase | |||
86 | miR-targeted genes in leukocytes - TarBase | |||
87 | miR-targeted genes in epithelium - TarBase | |||
88 | IL-1 signaling pathway | |||
89 | Signal amplification | |||
90 | Platelet homeostasis | |||
91 | Myogenesis | |||
92 | DSCAM interactions | |||
93 | Angiogenesis | |||
94 | Regulation of toll-like receptor signaling pathway |
